Tags

Type your tag names separated by a space and hit enter

IgM and IgG antibodies to hepatitis E virus (HEV) detected by an enzyme immunoassay based on an HEV-specific artificial recombinant mosaic protein.
J Med Virol. 1996 Sep; 50(1):50-8.JM

Abstract

To develop an enzyme immunoassay (EIA) for IgM antibody to hepatitis E virus (HEV) (IgM anti-HEV) and IgG antibody to HEV (IgG anti-HEV), a synthetic gene encoding several liner immunodominant antigenic epitopes from HEV structural proteins was assembled as a chimeric recombinant mosaic protein (Mpr) with glutathione S-transferase and used as an immunodiagnostic target. In addition, a neutralization confirmation test was developed using individual synthetic peptides. Among 614 patients with acute hepatitis from 10 geographically distinct outbreaks, IgG anti-HEV was found in 546 (88.9%), with a range of 77-100% depending on the outbreak. Of 130 patients tested for IgM anti-HEV, 126 (96.9%) were positive. Among patients tested within 4 months of onset of jaundice, 37/37 (100%) were IgG anti-HEV positive. For patients from whom sera were collected 1-16 days after onset of jaundice, the geometric mean IgG titer (GMT) was 1:47,000; the GMT increased to 1:70,710 30-40 days after onset of jaundice and decreased to 1:1,778 3-4 months after the onset of jaundice. For patients tested 6-8 months after onset of jaundice, 11/12 (92%) were IgG anti-HEV positive, and the GMT was 1:2,908. IgM anti-HEV was detected in 43/43 (100%) sera collected 1-40 days after onset of jaundice, and the GMT for IgM anti-HEV was 1:10,000 at that time. For sera collected 3-4 and 6-12 months after onset of jaundice, 7/14 (50%) and 5/12 (40%) respectively, were IgM anti-HEV positive. In conclusion, an artificial mosaic protein composed of linear antigenic epitopes from open reading frame 2 (ORF2) and ORF3 of HEV has been successfully applied to the development of a sensitive and specific EIA for the detection of IgG and IgM anti-HEV activity. These assays were used for the verification of HEV infection in outbreak settings and for the diagnosis of HEV infection in sporadic cases.

Authors+Show Affiliations

Hepatitis Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

8890041

Citation

Favorov, M O., et al. "IgM and IgG Antibodies to Hepatitis E Virus (HEV) Detected By an Enzyme Immunoassay Based On an HEV-specific Artificial Recombinant Mosaic Protein." Journal of Medical Virology, vol. 50, no. 1, 1996, pp. 50-8.
Favorov MO, Khudyakov YE, Mast EE, et al. IgM and IgG antibodies to hepatitis E virus (HEV) detected by an enzyme immunoassay based on an HEV-specific artificial recombinant mosaic protein. J Med Virol. 1996;50(1):50-8.
Favorov, M. O., Khudyakov, Y. E., Mast, E. E., Yashina, T. L., Shapiro, C. N., Khudyakova, N. S., Jue, D. L., Onischenko, G. G., Margolis, H. S., & Fields, H. A. (1996). IgM and IgG antibodies to hepatitis E virus (HEV) detected by an enzyme immunoassay based on an HEV-specific artificial recombinant mosaic protein. Journal of Medical Virology, 50(1), 50-8.
Favorov MO, et al. IgM and IgG Antibodies to Hepatitis E Virus (HEV) Detected By an Enzyme Immunoassay Based On an HEV-specific Artificial Recombinant Mosaic Protein. J Med Virol. 1996;50(1):50-8. PubMed PMID: 8890041.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - IgM and IgG antibodies to hepatitis E virus (HEV) detected by an enzyme immunoassay based on an HEV-specific artificial recombinant mosaic protein. AU - Favorov,M O, AU - Khudyakov,Y E, AU - Mast,E E, AU - Yashina,T L, AU - Shapiro,C N, AU - Khudyakova,N S, AU - Jue,D L, AU - Onischenko,G G, AU - Margolis,H S, AU - Fields,H A, PY - 1996/9/1/pubmed PY - 2000/6/20/medline PY - 1996/9/1/entrez SP - 50 EP - 8 JF - Journal of medical virology JO - J Med Virol VL - 50 IS - 1 N2 - To develop an enzyme immunoassay (EIA) for IgM antibody to hepatitis E virus (HEV) (IgM anti-HEV) and IgG antibody to HEV (IgG anti-HEV), a synthetic gene encoding several liner immunodominant antigenic epitopes from HEV structural proteins was assembled as a chimeric recombinant mosaic protein (Mpr) with glutathione S-transferase and used as an immunodiagnostic target. In addition, a neutralization confirmation test was developed using individual synthetic peptides. Among 614 patients with acute hepatitis from 10 geographically distinct outbreaks, IgG anti-HEV was found in 546 (88.9%), with a range of 77-100% depending on the outbreak. Of 130 patients tested for IgM anti-HEV, 126 (96.9%) were positive. Among patients tested within 4 months of onset of jaundice, 37/37 (100%) were IgG anti-HEV positive. For patients from whom sera were collected 1-16 days after onset of jaundice, the geometric mean IgG titer (GMT) was 1:47,000; the GMT increased to 1:70,710 30-40 days after onset of jaundice and decreased to 1:1,778 3-4 months after the onset of jaundice. For patients tested 6-8 months after onset of jaundice, 11/12 (92%) were IgG anti-HEV positive, and the GMT was 1:2,908. IgM anti-HEV was detected in 43/43 (100%) sera collected 1-40 days after onset of jaundice, and the GMT for IgM anti-HEV was 1:10,000 at that time. For sera collected 3-4 and 6-12 months after onset of jaundice, 7/14 (50%) and 5/12 (40%) respectively, were IgM anti-HEV positive. In conclusion, an artificial mosaic protein composed of linear antigenic epitopes from open reading frame 2 (ORF2) and ORF3 of HEV has been successfully applied to the development of a sensitive and specific EIA for the detection of IgG and IgM anti-HEV activity. These assays were used for the verification of HEV infection in outbreak settings and for the diagnosis of HEV infection in sporadic cases. SN - 0146-6615 UR - https://www.unboundmedicine.com/medline/citation/8890041/IgM_and_IgG_antibodies_to_hepatitis_E_virus__HEV__detected_by_an_enzyme_immunoassay_based_on_an_HEV_specific_artificial_recombinant_mosaic_protein_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0146-6615&date=1996&volume=50&issue=1&spage=50 DB - PRIME DP - Unbound Medicine ER -